Literature DB >> 15655118

Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition.

Céline Bouvet1, Liz-Ann Gilbert, Daphné Girardot, Denis deBlois, Pierre Moreau.   

Abstract

In essential hypertension, conduit arteries present hypertrophic remodeling (increased cross-sectional area), whereas small arteries undergo eutrophic remodeling. The involvement of matrix metalloproteinases (MMPs) and de-adhesion proteins, such as tenascin-C and thrombospondin, has been relatively well characterized in large artery remodeling, but their contribution is not known in small artery remodeling. Rats received N(omega)-nitro-L-arginine methyl ester (L-NAME; 50 mg/kg per day) in their drinking water on days 1, 3, 7, 14, and 28. Arterial MMP-2 activity was measured by ELISA, whereas levels of tenascin-C and thrombospondin were assessed by Western blotting. To determine the involvement of MMPs, additional L-NAME rats received the nonselective MMP inhibitor doxycycline (30 mg/kg per day) on days 7, 14, and 28. Already, at day 1, pressure was elevated. Media/lumen ratio of mesenteric arteries and the aorta increased gradually to reach significance at 28 days. However, the cross-sectional area increased only in the aorta, confirming the heterogeneous remodeling process. In small arteries, MMP-2 activity increased after 7 and 14 days of treatment and returned to baseline at 28 days, whereas the elevation was more progressive but sustained in the aorta. The level of thrombospondin paralleled that of MMP-2 in small arteries, whereas tenascin-C levels declined rapidly and stayed below control values. Doxycycline blunted large artery remodeling but had no influence on the development of eutrophic remodeling despite elevation of MMP-2 activity in the process. Thus, in contrast to large artery hypertrophic remodeling, in which the contributions of cellular de-adhesion and matrix breakdown is manifest, the contribution of MMPs in eutrophic remodeling appears less crucial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655118     DOI: 10.1161/01.HYP.0000154680.44184.01

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

1.  Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.

Authors:  C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

3.  Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall.

Authors:  Karola Trescher; Barbara Thometich; Svitlana Demyanets; Hermann Kassal; Roland Sedivy; Reginald Bittner; Christoph Holzinger; Bruno K Podesser
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-08

4.  Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR.

Authors:  Raquel C Antonio; Carla S Ceron; Elen Rizzi; Eduardo B Coelho; Jose E Tanus-Santos; Raquel F Gerlach
Journal:  Mol Cell Biochem       Date:  2013-10-10       Impact factor: 3.396

5.  Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.

Authors:  Diogo M O Marçal; Elen Rizzi; Alisson Martins-Oliveira; Carla S Ceron; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-31       Impact factor: 3.000

6.  Euterpe oleracea Mart.-derived polyphenols prevent endothelial dysfunction and vascular structural changes in renovascular hypertensive rats: role of oxidative stress.

Authors:  Cristiane Aguiar da Costa; Paola Raquel Braz de Oliveira; Graziele Freitas de Bem; Lenize Costa Reis Marins de Cavalho; Dayane Teixeira Ognibene; Andréa Fernandes Emiliano da Silva; Samuel Dos Santos Valença; Karla Maria Pereira Pires; Pergentino José da Cunha Sousa; Roberto Soares de Moura; Angela Castro Resende
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-09       Impact factor: 3.000

7.  Matrix metalloproteinases and small artery remodeling.

Authors:  Luis A Martinez-Lemus; Edgar Luis Galiñanes
Journal:  Drug Discov Today Dis Models       Date:  2011

Review 8.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

9.  Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function.

Authors:  Poulami Basu; Utpal Sen; Neetu Tyagi; Suresh C Tyagi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 10.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.